Who owns Editas Medicine, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of EDIT from SEC Form 13F filings across 219 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 219 institutions disclosed 139.5M shares of Editas Medicine, Inc. worth $356.5M — about 90.8% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
219
13F holders
$356.5M
value, 2026 filers
90.8%
of shares outstanding (139.5M sh)
34
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of EDIT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 14.4M | $37.0M | 0.0% | 9.4% | +36.0% |
| 2 | TCG Crossover Management, LLC | 11.1M | $28.6M | 0.8% | 7.2% | 0.0% |
| 3 | ADAR1 Capital Management, LLC | 8.9M | $22.8M | 1.0% | 5.8% | 0.0% |
| 4 | Commodore Capital LP | 8.9M | $22.8M | 1.8% | 5.8% | 0.0% |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 8.9M | $22.8M | 0.2% | 5.8% | 0.0% |
| 6 | Paradigm Biocapital Advisors LP | 7.6M | $19.5M | 0.4% | 4.9% | +35.6% |
| 7 | STATE STREET CORP | 7.0M | $18.1M | 0.0% | 4.6% | +221.1% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 6.1M | $15.6M | 0.0% | 4% | -1.1% |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7M | $12.0M | 0.0% | 3% | +30.1% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 3.9M | $10.0M | 0.0% | 2.5% | +51.4% |
| 11 | Woodline Partners LP | 3.6M | $9.1M | 0.0% | 2.3% | 0.0% |
| 12 | Vivo Capital, LLC | 3.6M | $9.1M | 1.0% | 2.3% | 0.0% |
| 13 | Opaleye Management Inc. | 3.5M | $9.0M | 1.0% | 2.3% | -9.7% |
| 14 | GOLDMAN SACHS GROUP INC | 3.2M | $8.3M | 0.0% | 2.1% | +24.1% |
| 15 | D. E. Shaw & Co., Inc. | 3.2M | $8.2M | 0.0% | 2.1% | +67.8% |
| 16 | GordonMD Global Investments LP | 3.1M | $8.0M | 4.8% | 2% | 0.0% |
| 17 | MARSHALL WACE, LLP | 3.0M | $7.8M | 0.0% | 2% | +48.5% |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 2.5M | $6.4M | 0.0% | 1.6% | +1.2% |
| 19 | Logos Global Management LP | 2.2M | $5.7M | 0.3% | 1.4% | 0.0% |
| 20 | Seven Fleet Capital Management LP | 1.9M | $2.9M | 0.6% | 1.2% | +44.0% |
| 21 | JPMORGAN CHASE & CO | 1.9M | $4.8M | 0.0% | 1.2% | +0.2% |
| 22 | UBS Group AG | 1.4M | $3.7M | 0.0% | 0.9% | +90.1% |
| 23 | TWO SIGMA INVESTMENTS, LP | 1.3M | $3.4M | 0.0% | 0.9% | -1.0% |
| 24 | RAYMOND JAMES FINANCIAL INC | 1.3M | $3.4M | 0.0% | 0.9% | -0.1% |
| 25 | KENNEDY CAPITAL MANAGEMENT LLC | 1.3M | $3.3M | 0.1% | 0.8% | +26.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.